What is the role of oral psoralen plus UV-A (PUVA) therapy in the management of mastocytosis?

Updated: Sep 16, 2020
  • Author: Jacquiline Habashy, DO, MSc; Chief Editor: Dirk M Elston, MD  more...
  • Print

Oral psoralen plus UV-A (PUVA) therapy results in general and cosmetic benefits in the treatment of cutaneous mastocytosis, [42] particularly telangiectasia macularis eruptiva perstans (TMEP); however, risks are involved, such as skin cancer if more than 200 treatments are required. The manifestations of the disease usually recur several months after discontinuation of PUVA, but recurrences respond as well as the original lesions. PUVA rarely is required in children. Currently, PUVA is reserved for severe, unresponsive cases in adults. In a 2003 study, medium-dose UV-A1 therapy was shown to be as effective as high-dose UV-A1 in reducing symptoms and the number of mast cells in affected skin. [43]  Narrowband UV-B has also been used. [44]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!